StemCell Therapy

The Ibex Second Read System for breast is now deployed at Maccabi's pathology institute, making it the first lab in the world to implement AI-powered cancer diagnostics for breast biopsies in its routine clinical practice

Tel Aviv, Israel /PRNewswire/ - Ibex Medical Analytics, the pioneer in artificial intelligence (AI)-powered cancer diagnostics, and the KSM Research and Innovation Institute at Maccabi Healthcare Services, announce the deployment of the Ibex Second Read System for breast at Maccabi's pathology institute, the largest pathology lab in Israel.

Ibex Second Read is the first-ever system that detects and grades cancer in breast biopsies. The system uses an artificial intelligence (AI) powered algorithm to analyze cases in parallel to pathologists and compares between the pathologists' diagnoses and the algorithm's findings, subsequently alerting in case of discrepancies with high clinical importance (e.g. a missed cancer). Now used in routine clinical practice, this clinical-grade product enhances the quality control process in the lab and provides a safety net, resulting in decreased diagnostic error rates and a more efficient workflow.

The algorithm used by the Second Read system was developed by Ibex using advanced machine learning techniques and trained on data sets from Maccabi's pathology institute. The institute was the first pathology lab in the world to implement an AI powered cancer diagnostic system in its routine practice - the Ibex Second Read system for prostate which is now deployed in pathology labs worldwide with demonstrated success in detecting missed cancer cases.

"We are proud to roll out a first of a kind product that improves the diagnosis of breast cancer - the most common cancer in women with over 2 million new cases globally each year. The Second Read for breast is a landmark achievement for our team of pathologists, computer scientists and AI specialists and for our partnership with Maccabi Healthcare Services, enabling us to extend the reach of our product suite. The future looks brighter than ever for Ibex, with a growing interest from pathology labs in our products and new tissue types we expect to introduce during 2020" said Joseph Mossel, Ibex Medical Analytics' Co-Founder and CEO.

"We are excited to use the Second Read system for breast cancer detection in our routine practice following a successful research and partnership with Ibex, led by the KSM Research and Innovation Institute. At Maccabi Healthcare Services we are constantly looking for new technologies that can make a real impact on patient care. We believe that adding a security layer to our pathology reporting will improve accuracy levels of our cancer diagnosis, as already proven by the Second Read's prostate module that we have been using in the past 18 months," said Prof. Varda Shalev, Managing Director of the Kahn-Sagol-Maccabi Research and Innovation Institute at Maccabi Healthcare Services.

About Ibex Medical AnalyticsIbex provides the first-ever AI-powered cancer diagnostics solution in routine clinical use in pathology labs, supporting pathologists in delivering accurate, rapid and objective diagnosis of prostate and breast biopsies. Ibex' product is deployed across the laboratory's workflow and builds on deep learning algorithms developed by a team of pathologists, data scientists and software engineers. The company has raised $14 million from prominent VC funds and corporate investors. For more information visit us at http://www.ibex-ai.com.

About Maccabi Healthcare ServicesMaccabi Healthcare Services is one of the world's largest healthcare providers with 2.5 million members. Maccabi has long been recognized, both in Israel and abroad, as a unique and innovative health care system which leads the way in cutting edge medical technology, comprehensive and integrated computerized information systems, costeffective management and sophisticated monitoring and evaluation tools.

The Kahn-Sagol-Maccabi Research and Innovation Institute's vision is to accelerate precision medicine and lead in big data analytics. We aim to increase the amount and quality of medical research being performed at any given moment in Israel and worldwide and partner with the most advanced AI companies to develop innovative, predictive and personalized tools in service of the new era of medicine.

Continued here:
Ibex Medical Analytics And The Kahn-Sagol-Maccabi (KSM) Research And Innovation Institute At Maccabi Healthcare Services Roll Out The First-Ever...

December has always been a time for reflection and anticipation for whats to come the following year. Considering that 2020 marks the beginning of a brand new decade, theres extra excitement for what the year will bring and what tone it will set for the entire decade. It seems that every year is an exciting year for the pharma industry and 2020 stays on course. Pharma professionals have many exciting trends to monitor for the year ahead.

Perhaps the most noteworthy trend of them all is the prevalence of China on the pharma market in the first place. For decades, China has not been a major player certainly no source for meaningful innovation or trendsetting power. This, however, has changed dramatically in the last decade as the government heavily invested in the biopharma industry, which has seen the Chinese market grow by an estimate 25% annually over the course of five years between 2012 and 2016. Current estimations place the value of the market to hit USD $48.8 billion by 2021.

These numbers alone should alert the international community at large to pay attention, especially when it seems that Chinas main priority is the developments in bio-processing with the export of biologics identified as a chief objective.

Preventive healthcare and personalized medicine are also picking up steam. Not every disease can be cured, which is where pharmaceutical innovations strive to prevent its contraction. Perhaps the most significant success that preventive medicine has observes is with HIV. Products like Truvada have made all the difference in slowing down the spread of the virus. This approach is only going to come to the forefront in coming years. In the same breath, the pharmaceutical industry has set its sights on improving health care through personalized medicine, which breaks away from the average and investigates deeper the unique biodome of the patient. The technology relied on full patient data and customized medicines to create a custom-tailored treatment.

Were not in the 21st century, if we dont speak about AI and digitalisation as part of Industry 4.0 in relation to pharmaceuticals. Artificial Intelligence is already poised to become the tool that will win margins and improve budget spending. Its no secret that the pharmaceutical industry is in dire need of improving efficiency in order to reduce its wastefulness and AI is being developed to then handle these processes.

Digital solutions are set to help with breakthroughs in the Value Added Medicines (VAM) sector through an improvement in patient reports. Given the rise of medical wearable technology, it will be easier to collect real patient usage metrics to support VAM players in the long run.

The safest way to gain a deep insight into pharma trends is to attend the trade shows known for a higher commitment to informing its audience about how their professional landscape is changing.

CPhI Worldwide:

Perhaps the first event anyone involved in pharmaceuticals thinks about. The unique feature here is the distinct separation of CPhI Worldwide into six areas that in turn embody each of the pharmaceutical supply chain stages. This allows for more in-depth digging and research into highly specialized trends.

Expopharm: As a leading meeting point for the actors on the global pharmaceutical market, Expopharm presents a full picture of the dynamic market trends and is also a platform for exhibitors to make announcements regarding their personal technological innovations.

MEDICA: Held alongside COMPAMED, MEDICA is the umbrella trade show where the whole of medicine is represented and in that sense youll experience pharmaceutical news and trends in relation to the broader medical and technological fields.

IDS: IDS enjoys a reputation of the most important dentistry trade show in the world, so if youre specialized in dentistry pharmaceuticals IDS is where you need to come to receive highly targeted news, product launches and announcements.

Arab Health: The MENA region has been known for its high-paced rates of innovation and Arab Health is an entry point into a highly competitive market that has its own, entirely different feel. Some trends and innovations are first talked about during this show.

But what about vitamins and supplements?

Adjacent to pharmaceuticals, but not as heavily regulated are the markets for essential supplements and vitamins, which are also in the great throes of transformation for the upcoming year. Were in for the year of watermelon seeds, which have emerged as the surprise super food recently, and a fervent love of all things moringa. The markets that are shaping up to be big earners are the sleep supplements and pet supplements. Whatever you decide to put into your body should be the very best and in that sense its good to have a list of supplement brands that have been recognized for their high quality.

Go here to read the rest:
It's Going to Be a Big Year for Pharma Trends in 2020 Here's What to Watch out For - - VENTS Magazine

Company also announces CRISPR Therapeutics CEO Samarth Kulkarni, Ph.D., Joins its Board of Directors

CAMBRIDGE, Mass. and NEW YORK, Dec. 5, 2019 /PRNewswire/ --Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the completion of an oversubscribed Series C financing of $85 million led by Boxer Capital of the Tavistock Group. Additional new investors Wellington Management Company, BVF Partners L.P., Deerfield Management, funds managed by Janus Henderson Investors, Casdin Capital, and Logos Capital joined current investors Versant Ventures, New Enterprise Associates, RA Capital Management, Nextech Invest, Invus, Perceptive Advisors, City Hill Ventures, and Roche Venture Fund in the round.

Black Diamond Therapeutics Logo (PRNewsfoto/Black Diamond Therapeutics, Inc.)

Proceeds from the Series C financing will be used to support the Company's growth and advance the development of Black Diamond's lead product candidates targeting oncogenic driver mutations of the ErbB kinases in epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). The Company plans to start a combined Phase 1/2 clinical trial of its most advanced product candidate, BDTX-189, in the first half of 2020. The funding will also support the continued expansion of the Company's earlier stage research programs and proprietary Mutation-Allostery-Pharmacology (MAP) platform to identify and target oncogenic mutations. The Company initially operated in stealth mode from New York and from Versant's Basel-based Ridgeline Discovery Engine and has raised $194 million since its founding.

David M. Epstein, President and CEO of Black Diamond commented, "We are privileged to have this impressive syndicate of thought-leading investors share our commitment to patients and support our vision to discover and develop therapies that will potentially transform how cancer is treated. There arecurrently no drugs approved by the FDA to target certain allosteric and other EGFR and HER2 mutations that are prevalent in a variety of cancers with a single therapy, including in patients with deadly cancers like lung cancer or glioblastoma that express these mutations. This funding will help accelerate development of our lead product candidates targeting undrugged oncogenic driver mutations of EGFR and HER2 so that we can get potential new treatments to patients as quickly as possible."

Commenting on the investment, Aaron Davis, CEO of Boxer Capital said, "Black Diamond's ground-breaking MAP platform could revolutionize how we discover and develop new oncology treatments, particularly for some of the most difficult-to-treat cancers. We are delighted to partner with this group of leading investors and experienced management team in this endeavor."

In addition, Black Diamond announced the appointment of Samarth (Sam) Kulkarni, Ph.D., to its Board of Directors. An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Sam currently serves as CEO of CRISPR Therapeutics AG. Hejoined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before being named its CEO in 2017.

Story continues

"We are thrilled to have Sam join Black Diamond's Board of Directors. His wealth of experience and proven track record of strategic business accomplishments and advancing innovative therapeutic technologies will be invaluable as we continue to progress our portfolio and design our programs for clinical success," added Dr. Epstein.

Prior to CRISPR, Sam was a partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotechnology practice and focused on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer. He received a Ph.D. in bioengineering and nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, Sam conducted research on the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.

"It is an exciting time to be joining Black Diamond'sBoard of Directors. The Company has tremendous momentum and I believe has significant potential to change how we treat cancer through its MAP platform and discovery engine," said Dr. Kulkarni.

Black Diamond's MAP platformBlack Diamond's Mutation-Allostery-Pharmacology (MAP) platform is built on three central pillars discover, reveal, and target. The Company uses population-level cancer genetic data obtained from all tumor types to identify potential families of mutations that occur within individual oncogenes and rank the mutations for potential oncogenicity. Black Diamond then uses its MAP platform to understand the mechanism for oncogenic activation and its team of experienced medicinal chemists then develops mutation spectrum-selective drugs for the identified targets.

Black Diamond's MAP platform has generated a pipeline of orally available, potent, and selective small molecule kinase inhibitors that target a range of driver mutations in cancer. The Company'sfirst two disclosed programs are targeting groups of EGFR and HER2 allosteric mutants.

About Black DiamondBlack Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information please visit http://www.bdtherapeutics.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/black-diamond-therapeutics-closes-85-million-series-c-financing-300969326.html

SOURCE Black Diamond Therapeutics, Inc.

Originally posted here:
Black Diamond Therapeutics Closes $85 Million Series C Financing - Yahoo Finance

The report on the Personalized Medicine Market published by Future Market Insights (FMI) provides a clear understanding of the flight of the Personalized Medicine Market over the forecast period 2016 2026. The study introspects the various factors that are tipped to influence the growth of the Personalized Medicine market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the Personalized Medicine Market are analyzed in the report.

The study reveals that the global Personalized Medicine Market is projected to reach a market value of ~US$XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the Personalized Medicine Market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.futuremarketinsights.co/reports/sample/REP-GB-1511

Key Takeaways of the Report:

The report addresses the following doubts related to the Personalized Medicine Market:

Get Access To TOC Covering 200+ Topics athttps://www.futuremarketinsights.co/toc/REP-GB-1511

Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customized Report As Per Your Requirements athttps://www.futuremarketinsights.co/customization-available/REP-GB-1511

Why Choose FMI Research?

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

616 Corporate Way, Suite 2-9018,Valley Cottage, NY 10989,United StatesT: +1-347-918-3531F: +1-845-579-5705T (UK): + 44 (0) 20 7692 8790

Link:
Personalized Medicine Market expected to be valued at ~US$ XX Mn/Bn during the forecast period 2016 2026 - Weekly News Times

Washington (AFP)

In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering -- by editing her genome.

Victoria Gray's recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research -- gene therapy.

"I have hoped for a cure since I was about 11," the 34-year-old told AFP in an email.

"Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency."

Over several weeks, Gray's blood was drawn so doctors could get to the cause of her illness -- stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 -- pronounced "Crisper" -- a new tool informally known as molecular "scissors."

The genetically edited cells were transfused back into Gray's veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary but, theoretically, she has been cured.

"This is one patient. This is early results. We need to see how it works out in other patients," said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

"But these results are really exciting."

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease, beta thalassemia. She had previously needed 16 blood transfusions per year.

Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified.

But Crispr, invented in 2012, made gene editing more widely accessible. It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

"It's all developing very quickly," said French geneticist Emmanuelle Charpentier, one of Crispr's inventors and the cofounder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

- Cures -

Crispr is the latest breakthrough in a year of great strides in gene therapy, a medical adventure started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not -- such as making normal red blood cells, in Victoria's case, or making tumor-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies -- bringing the total to eight -- approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

"Twenty-five, 30 years, that's the time it had to take," he told AFP from Paris.

"It took a generation for gene therapy to become a reality. Now, it's only going to go faster."

Just outside Washington, at the National Institutes of Health (NIH), researchers are also celebrating a "breakthrough period."

"We have hit an inflection point," said Carrie Wolinetz, NIH's associate director for science policy.

These therapies are exorbitantly expensive, however, costing up to $2 million -- meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion -- and fighting a general infection.

"You cannot do this in a community hospital close to home," said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to MIT researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

- Bioterrorism -

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who don't necessarily share the medical ethics of Western medicine.

Last year in China, scientist He Jiankui triggered an international scandal -- and his excommunication from the scientific community -- when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV, even though there was no specific reason to put them through the process.

"That technology is not safe," said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr "scissors" often cut next to the targeted gene, causing unexpected mutations.

"It's very easy to do if you don't care about the consequences," Musunuru added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species -- malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully, however, fully aware of the unpredictability of chain reactions on the ecosystem.

Charpentier doesn't believe in the more dystopian scenarios predicted for gene therapy, including American "biohackers" injecting themselves with Crispr technology bought online.

"Not everyone is a biologist or scientist," she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies' crops?

Charpentier thinks that technology generally tends to be used for the better.

"I'm a bacteriologist -- we've been talking about bioterrorism for years," she said. "Nothing has ever happened."

2019 AFP

Read more:
2019: the year gene therapy came of age - FRANCE 24

Fiormarketshas announced a new market research study namelyGlobalStem Cell ReconstructiveMarket Growth 2019-2024which includes an executive summary, definition, and scope of the market. The report contains the historical data and its comparison with the current market scenario to provide the trajectory this market will take in the forecast period from 2019 to 2024. The report contains various aspects of theStem Cell Reconstructivemarket such as product price, product classification, covering major sectors of the market. The report presents a deep scenario on the current state focusing on the major drivers and restraints and its impact analysis for the key players. This professional study detects the major aspects like drivers, restraints, industry development patterns, scope, qualities, shortcomings, openings, and dangers using a SWOT examination.

DOWNLOAD FREE SAMPLE REPORT :https://www.fiormarkets.com/report/global-stem-cell-reconstructive-market-growth-status-and-382312.html#sample

Overview of The Report:

The report separates the market by the top manufacturer, end-users, and their application in accordance with their respective data including market size & forecast, consumption, sales revenue, price, gross margin, supply and demand by region, and consumer profile. The report highlights theStem Cell Reconstructivemarket definition, taxonomy, and an overview of the parent market across the globe and region wise. Geographical data will help the reader understand the best performing regions. This report further studies the global market status, completion landscape, market share, growth rate, future trends, and sales channels. The report mainly comprises the major company profiles with their annual sales & revenue, business strategies, company major products, profits, industry growth parameters, industry contribution on a global and regional level.

Key playersmentioned in the globalStem Cell Reconstructivemarket research report:Osiris Therapeutics, NuVasive, Cytori Therapeutics, Takeda (TiGenix), Cynata, Celyad, Medi-post, Anterogen, Molmed

Key Factors Offered By Our Report Are:

ACCESS FULL REPORT :https://www.fiormarkets.com/report/global-stem-cell-reconstructive-market-growth-status-and-382312.html

This report offers an examination and increment pace of the market in these districts covering:Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries).

Moreover, the report includes other pointers such as the current industry policies in conjunction with the topographical industry layout characteristics.TheStem Cell Reconstructiveindustry also gives expert insights to help the reader work on their competitive strategy and make better executive decisions. The research study will help you in managing and running current occupational strategies.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team(sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

See the article here:
Global Stem Cell Reconstructive Market 2019 | Industry Future Growth, Key Player Analysis and Forecast 2024 - News Midget

When Merck was hit with a ransomware attack in 2017, the pharma giant was in fact just collateral damage from a virus Russia aimed at Ukraine, and the company is struggling to recoup its losses because its $1.75 billion insurance plan doesnt cover acts of war.

Those are details from a richly reported Bloomberg Newsstory out yesterday exploring how a geopolitical fight in Eastern Europe accidentally entangled a New Jersey-based pharmaceutical company and sparked lawsuits with major ramifications for the future of insurance and cybercrime.

Merck employees logging on to their computers on June 27, 2017 were greeted with a polite message in pink letters: Ooops, your important files are encrypted. We guarantee that you can recover all your files safely and easily. All you need to do is submit the payment. The payment was $300 in bitcoin, per computer.

Early on, it was clear that Merck was one victim of a global attack that also hit Danish shipping company Maersk, American food company Mondelez, French construction giant Saint-Gobain and even the systems monitoring the Chernobyl nuclear power stations, among others.

Unlike Chernobyl, though, it appears that Merck was not an intended target. The attack was dubbed NotPetya, a creation of the GRU Russian military intelligence agency (the same one that attacked the Democratic National Committee), and it was designed to strike companies and agencies in Ukraine, a country that had been in conflict with Russia since 2014. But, per Bloomberg, NotPetya contaminated a tax software application, M.E.Doc, that was running on a server in Mercks Ukraine office.

From there, it spread to the pharma giants headquarters, where it would eliminate in some cases years of research, cripple Gardisal 9 production facilities and eventually cause (by Mercks estimate) $1.3 billion in damages. Merck, though, had a property insurance plan worth up to $1.75 billion that covered computer data, coding and software (after a $150 million deductible). But when Merck went to activate the plan, most of their 30 insurers rejected them. Your plan doesnt cover damages from military action, they told shocked Merck officials.

What followed were, not surprisingly,a string of lawsuits, with Merck claiming that it was hit by a cyber not a military event. These lawsuits, Bloomberg reports, are being watched for the precedents they may set around how future cybercrime is classified.

The insurers are trying to prove two things: that the attack really did come from Russia and that Merck was not as vigilant as it could have been in protecting their data. Merck, as Endpoints News reportedshortly after the attack, had missed two opportunities to inoculate themselves against the virus before they were struck.

On Russia, the insurers have gotten a hand from the White House. Last year, the Trump Administration wrote without equivocation that the attack was part of the Kremlins ongoing effort to destabilize Ukraine and demonstrates ever more clearly Russias involvement in the ongoing conflict.

When the president of the United States comes out and says, Its Russia, its going to be hard to fight, Jake Williams, a former National Security Agency hacker who now helps companies hunt for vulnerabilities in their computer networks, told Bloomberg. Ill be surprised if the insurance companies dont get a win. This is as solid a case as theyre going to get.

But some legal experts expressed greater skepticism of the insurers case. All signs may point to Russian culpability but when it comes to cyber, its not clear what military action means.

Its not going to be an easy case for a judge in the U.S. to declare that this was an act of war, Catherine Lotrionte, a former CIA lawyer whos taught at Georgetown University, told Bloomberg.

More:
Merck in $1.3B showdown with insurers over 2017 ransomware attack Bloomberg - Endpoints News

A working group of rheumatologists and rheumatology professionals convened to update the American College of Rheumatology (ACR) recommendations for rheumatoid arthritis (RA) disease activity measures by identifying 11 measures that met the minimum standard and 5 that were preferred for regular use in clinical settings, according to a systematic literature review published in Arthritis Care & Research.1

Researchers examined articles published between January 2009 and January 2017 on the Ovid Medline, EMBASE, and Cochrane databases. Study details and psychometric properties were abstracted, and study quality was assessed by the Consensus-Based Standards for the Selection of Health Measurement Instruments 4-point scoring template. Psychometric properties for each RA disease activity measure were classified as strong, moderate, limited, conflicting, or unknown level of evidence. Researchers also considered prior literature performed as part of the 2012 ACR RA Disease Activity Recommendations.2 They scored feasibility of RA disease activity measures on a scale of 0 to 4, with scores 1 indicating measures feasible for regular use and scores of 4 indicating the most feasible measures.

During the selection process, researchers identified 2 recommendations on RA disease activity measures for use in clinical settings: measures that met a minimum standard for regular use and measures with the most favorable psychometric properties and feasibility for preferred use.

Of the 5199 articles identified, 110 met the study inclusion criteria. Data included in these studies indicated that patients were mostly women with a mean age 60 years.

The search resulted in 47 disease activity measures, based on patient-reported, provider assessment, laboratory, and imaging data. Clinical Disease Activity Index (CDAI), Disease Activity Score (DAS) 28, Multibiomarker Disease Activity (MBDA) score, Routine Assessment of Patient Index Data (RAPID) 3, and Simplified Disease Activity Index (SDAI) were the most frequently studied RA disease activity measures, with a strong level of evidence. Among 25 measures scored for feasibility of regular use, 11 (44%) received the highest grading score of 4, 6 measures (24%) received a score of 3, 5 (20%) received a score of 2, and 3 (12%) received a score of 1.

Researchers found that 11 measures, including CDAI, DAS, DAS28-erythrocyte sedimentation rate/C-reactive protein (ESR/CRP), Patient Derived DAS28, Hospital Universitario La Princesa Index, MBDA (MBDA score, VECTRA), Rheumatoid Arthritis Disease Activity Index (RADAI), RADAI-5, RAPID3, RAPID5, and SDAI, met the minimum criteria for RA disease activity measures for regular use. Among these, CDAI, DAS28-ESR/CRP, RAPID3, and SDAI were part of the prior ACR recommendations for RA disease activity measures.

According to results from the modified Delphi voting process, 4 measures, including CDAI, DAS28, RAPID3, and SDAI (mean scores, 8.8, 7.6, 7.6, 7.6 [range, 2.6-5.6], respectively), met the criteria for RA disease activity measures for preferred use. The ACR Quality Measures Subcommittee added another recommendation to these measures, based on its feasibility, current use, and strength of inclusion in previous ACR recommendations: Patient Activity Scale-II.

These recommendations can assist clinicians with adhering to a treat-to-target approach for the management of RA but should not be interpreted as dictating the proper measure to be used in individual circumstances or clinical practices. As additional measures are developed and performance of measures is further characterized, these recommendations should again be evaluated, the researchers concluded.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

References

1. England BR, Tiong BK, Bergman MJ, et al. 2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures [published online November 11, 2019]. Arthritis Care Res. doi:10.1002/acr.24042

2. Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity ScoreII (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index5 (RADAI5), Chronic Arthritis Systemic Index (CASI), PatientBased Disease Activity Score With ESR (PDAS1) and PatientBased Disease Activity Score Without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOIRA) [published online November 7, 2019]. Arthritis Care Res. doi:10.1002/acr.20621

Read the original:
Updated 2019 ACR Recommendations for Rheumatoid Arthritis Disease Activity Measures - Rheumatology Advisor

GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Tetra Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for patients with cognitive impairment and memory loss, today announced a poster presentation at the 12th Clinical Trials on Alzheimers Disease Meeting (CTAD) being held in San Diego, from December 4 7.

The poster, titled Tumor Necrosis Factor (TNF) Blocking Agents Reduce Risk for Alzheimers Disease in Patients with Rheumatoid Arthritis and Psoriasis, highlights data from a retrospective population-based study of 56 million patients in which inflammatory disease in the body is shown to increase risk for Alzheimers disease and that risk can be reduced in these patients by treatment with a TNF blocking drug. The study was conducted in conjunction with Case Western Reserve University.

Our analysis demonstrates the value of a large, population-based database covering 20% of the entire US population. We find that inflammation in the body increases risk for Alzheimers disease across multiple diseases involving the joints, the gut and the skin, said Mark E. Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra Therapeutics and co-author of the study. The study further indicates that the risk for Alzheimers disease can be reduced in patients with rheumatoid arthritis and psoriasis by treatment with TNF blocking agents such as etanercept, adalimumab, and infliximab. The results of our retrospective study need to be validated by well-controlled, prospective studies, but offer the hope that Alzheimers disease can be prevented in some patients in whom an inflammatory disease is a risk factor for developing Alzheimers disease.

The study used the de-identified population-level, electronic health records of 56 million unique patients collected by the IBM Watson Health Explorys Cohort Discovery platform from 360 hospitals and 317,000 providers. The study evaluated patients with inflammatory diseases (including rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel disease, ulcerative colitis, and Crohn's disease). The study examined whether these systemic inflammatory diseases - which in part are mediated by tumor necrosis factor (TNF) - increased the risk for Alzheimers disease and whether or not risk could be mitigated by an FDA-approved, TNF blocking biologic drug.

The study findings are exciting in that we clearly see that TNF blocking agents reduce the risk for co-morbid Alzheimers disease in real-world patients diagnosed with rheumatoid arthritis or psoriasis, said Rong Xu, Ph.D., Associate Professor, Department of Population and Quantitative Health Sciences, School of Medicine at Case Western Reserve University and co-author of the study. Given that anti-TNF biologics are powerful drugs, we believe further prospective studies are necessary to understand their potential in treating or preventing Alzheimer's disease.

The analysis compared a diagnosis of Alzheimer's disease as an outcome measure in patients who received at least one prescription for a TNF blocking agent (etanercept, adalimumab, and infliximab) or for methotrexate.

Alzheimer's risk was increased in adults with the following diagnoses (all P<0.0001):

Key findings:

About Alzheimers Disease and Tumor Necrosis Factor (TNF)

Alzheimers disease (AD) is the most common cause of dementia. Multiple lines of evidence indicate that TNF may trigger or amplify aberrant microglia signaling in the brain and thereby contribute to AD pathogenesis. Systemic inflammatory diseases affecting the joints, skin and gut are caused in part by the production of TNF by activated macrophages and these diseases can be treated effectively with a TNF blocking agent. Furthermore, systemic TNF can access the brain through receptor-mediated transcytosis. In the brain, elevation of tumor necrosis factor (TNF) in cerebrospinal fluid collected from subjects with mild cognitive impairment is associated with progression to AD at 6 months follow up.

About Tetra Therapeutics

Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Alzheimers disease, Fragile X Syndrome, traumatic brain injury, and other brain disorders. Tetra uses structure-guided drug design to discover mechanistically novel, allosteric inhibitors of phosphodiesterase 4 (PDE4), an enzyme family that plays key roles in memory formation, learning, neuroinflammation, and traumatic brain injury. Tetra Therapeutics is headquartered in Grand Rapids, Michigan. For more information, please visit tetratherapeutics.com.

Link:
Tetra Therapeutics Announces Presentation of Data from Retrospective Population-Based Study of 56 Million Patients at the 12th Clinical Trials on...

A research team led by biomedical scientists at the University of California, Riverside, has found that a drug approved by the FDA to treat rheumatoid arthritis and ulcerative colitis can repair permeability defects in the guts epithelium.

Affecting roughly 1 million Americans, ulcerative colitis is a chronic inflammatory bowel disease of the large intestine in which the lining of the colon becomes inflamed and leaky. Affecting more than 2 million Americans, rheumatoid arthritis is an autoimmune disease in which the bodys immune system attacks the joints.

The study is the first to show the drug, tofacitinib, also called Xeljanz, has a direct effect on cells lining the gut by correcting defects that occur in inflammation. Until now, the effects of tofacitinib on intestinal epithelial cell functions were largely unknown.

Our work increases our understanding of how this drug is useful for treating ulcerative colitis, said Declan McCole, a professor of biomedical sciences in the UCR School of Medicine, and the lead author of the study that appears in the journal Inflammatory Bowel Diseases. We now better understand where in the gut the drug is working, and how.

McCole explained that increased intestinal permeability or leakiness is a feature of ulcerative colitis and plays a critical role in promoting inflammation. His team tested tofacitinib in human intestinal epithelial cell lines, as well as in organoids, or colonoids, that were derived from primary human colonic stem cells isolated from human subjects primarily patients undergoing elective colonoscopy for colon cancer screening and found tofacitinib repaired inflammation-induced permeability defects in both.

The epithelium is a thin layer that lines the alimentary canal. The gastrointestinal epithelium is comprised of cells that have gaps between them, making them selectively permeable and providing a barrier that keeps out pathogens, toxins, and antigens from entering the gut, while allowing the absorption of nutrients. In ulcerative colitis, this epithelial permeability becomes leaky, allowing bacterial products to cross into the gut and nutrients and water to leak out. This, in turn, triggers immune responses, resulting in fluid loss and diarrhea.

We found tofacitinib fixes the leakiness in the intestinal barrier, McCole said. Specifically, it fixes intestinal epithelial permeability defects caused by interferon-gamma, an inflammatory cytokine involved in autoimmune diseases such as ulcerative colitis and rheumatoid arthritis.

By targeting specific molecules, the drug inhibits a pathway that is activated by inflammation, said Anica Sayoc-Becerra, a graduate student in the Biomedical Sciences Graduate Program, a member of McColes lab, and the first author of the research paper. Our study shows tofacitinib is not just acting on immune cells, as was first thought, but can have a direct effect on the epithelial cells that are the key factor in maintaining gut barrier function.

A major focus of McColes lab is PTPN2, a protein-coding gene associated with autoimmune diseases such as Crohns disease, ulcerative colitis, and rheumatoid arthritis. Individuals with mutations in this gene that cause it to lose function have an increased risk of getting these diseases. McColes research group was the first to identify PTPN2 normally helps to protect the barrier function of the epithelial cells that line the gut.

A patient that has a PTPN2 loss-of-function mutation is predicted to have a leakier gut, McCole said. Rather than trying to repair PTPN2, my lab was successful in inhibiting some of the consequences of the loss-of-function mutation in this gene.

Sayoc-Becerra explained PTPN2 deactivates the same signaling pathway as tofacitinib.

We thought tofacitinib might be a very effective way of correcting the defects that occur from the loss-of-function mutations of PTPN2 without having to introduce new genes into a cell, animal, or patient, she said.

McCole and Sayoc-Becerra were joined in the study by UC Riversides Moorthy Krishnan, Jossue Jimenez, Rebecca Hernandez, Kyle Gibson, and Reyna Preciado; as well as Shujun Fan and Grant Butt of the University of Otago in New Zealand. Sayoc-Becerra expects to graduate with her doctoral degree in December 2019. This is her first paper as first author.

Next, the researchers plan to identify specific patients who may derive the greatest benefit from the drug. This will allow more targeted treatment of patients likely to be good responders to tofacitinib in a personalized medicine approach to treating this disease.

Reference:Sayoc-Becerra, et al. (2019) The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction.Inflammatory Bowel Diseases DOI: https://doi.org/10.1093/ibd/izz266

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Drug Decreases Gut Leakiness Linked to Ulcerative Colitis - Technology Networks

A research team led by biomedical scientists at the University of California, Riverside, has found that a drug approved by the FDA to treat rheumatoid arthritis and ulcerative colitis can repair permeability defects in the guts epithelium.

Affecting roughly 1 million Americans, ulcerative colitis is a chronic inflammatory bowel disease of the large intestine in which the lining of the colon becomes inflamed and leaky. Affecting more than 2 million Americans, rheumatoid arthritis is an autoimmune disease in which the bodys immune system attacks the joints.

The study is the first to show the drug, tofacitinib, also called Xeljanz, has a direct effect on cells lining the gut by correcting defects that occur in inflammation. Until now, the effects of tofacitinib on intestinal epithelial cell functions were largely unknown.

Our work increases our understanding of how this drug is useful for treating ulcerative colitis, said Declan McCole, a professor of biomedical sciences in the UCR School of Medicine, and the lead author of the study that appears in the journal Inflammatory Bowel Diseases. We now better understand where in the gut the drug is working, and how.

McCole explained that increased intestinal permeability or leakiness is a feature of ulcerative colitis and plays a critical role in promoting inflammation. His team tested tofacitinib in human intestinal epithelial cell lines, as well as in organoids, or colonoids, that were derived from primary human colonic stem cells isolated from human subjects primarily patients undergoing elective colonoscopy for colon cancer screening and found tofacitinib repaired inflammation-induced permeability defects in both.

The epithelium is a thin layer that lines the alimentary canal. The gastrointestinal epithelium is comprised of cells that have gaps between them, making them selectively permeable and providing a barrier that keeps out pathogens, toxins, and antigens from entering the gut, while allowing the absorption of nutrients. In ulcerative colitis, this epithelial permeability becomes leaky, allowing bacterial products to cross into the gut and nutrients and water to leak out. This, in turn, triggers immune responses, resulting in fluid loss and diarrhea.

We found tofacitinib fixes the leakiness in the intestinal barrier, McCole said. Specifically, it fixes intestinal epithelial permeability defects caused by interferon-gamma, an inflammatory cytokine involved in autoimmune diseases such as ulcerative colitis and rheumatoid arthritis.

By targeting specific molecules, the drug inhibits a pathway that is activated by inflammation, said Anica Sayoc-Becerra, a graduate student in the Biomedical Sciences Graduate Program, a member of McColes lab, and the first author of the research paper. Our study shows tofacitinib is not just acting on immune cells, as was first thought, but can have a direct effect on the epithelial cells that are the key factor in maintaining gut barrier function.

A major focus of McColes lab is PTPN2, a protein-coding gene associated with autoimmune diseases such as Crohns disease, ulcerative colitis, and rheumatoid arthritis. Individuals with mutations in this gene that cause it to lose function have an increased risk of getting these diseases. McColes research group was the first to identify PTPN2 normally helps to protect the barrier function of the epithelial cells that line the gut.

A patient that has a PTPN2 loss-of-function mutation is predicted to have a leakier gut, McCole said. Rather than trying to repair PTPN2, my lab was successful in inhibiting some of the consequences of the loss-of-function mutation in this gene.

Sayoc-Becerra explained PTPN2 deactivates the same signaling pathway as tofacitinib.

We thought tofacitinib might be a very effective way of correcting the defects that occur from the loss-of-function mutations of PTPN2 without having to introduce new genes into a cell, animal, or patient, she said.

McCole and Sayoc-Becerra were joined in the study by UC Riversides Moorthy Krishnan, Jossue Jimenez, Rebecca Hernandez, Kyle Gibson, and Reyna Preciado; as well as Shujun Fan and Grant Butt of the University of Otago in New Zealand. Sayoc-Becerra expects to graduate with her doctoral degree in December 2019. This is her first paper as first author.

Next, the researchers plan to identify specific patients who may derive the greatest benefit from the drug. This will allow more targeted treatment of patients likely to be good responders to tofacitinib in a personalized medicine approach to treating this disease.

The research was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, as well as inflammatory bowel disease research awards from Pfizer Inc., the maker of tofacitinib.

Go here to read the rest:
Drug decreases gut leakiness associated with ulcerative colitis - UC Riverside

DUBLIN, Dec. 3, 2019 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs.

Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies.

As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030.

Amongst other elements, the report includes:

In order to provide a detailed future outlook, our projections have been segmented on the basis of:

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Regulatory Landscape

6. Stem Cell Therapy Contract Manufacturers In North America

7. Stem Cell Therapy Contract Manufacturers In Europe And Asia-Pacific

8. Partnerships And Collaboration

9. Contract Manufacturing Opportunity Assessment

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Key Performance Indicators

14. Concluding Remark

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List Of Companies And Organizations

For more information about this report visit https://www.researchandmarkets.com/r/jwfp7v

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-stem-cell-therapy-contract-manufacturing-market-research-2019-2030-source-of-stem-cells-types-of-stem-cells-size-of-contract-service-provider-company-scale-of-operation-key-regions-300968080.html

SOURCE Research and Markets

See original here:
Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service...

TOULOUSE, France--(BUSINESS WIRE)--Cell-Easy secures 1M capital investment and appoints Pierre Monsan as CEO. Thanks to its ground-breaking mesenchymal stem-cell large scale manufacturing process, Cell-Easy is set to democratise regenerative therapy, making treatments more affordable. The opening of its pharmaceutical plant is planned for the beginning of 2020 and the production of the first clinical batch later in the year.

Affordable treatments thanks to large scale manufacturingBased on the principles of cell therapy, regenerative medicine is shaking traditional medicine, offering treatments for previously incurable diseases. Taking by storm this fast growing market, the start-up Cell-Easy has raised 1M investment from private investors and experts and secured the appointment of Pierre Monsan as CEO and CSO (Chief Scientific Officer).

Pierre Monsan is Professor Emeritus at the INSA, Toulouse and Founder of Toulouse White Biotechnology (TWB) and of the French Federation of Biotechnology. He is confident in the future of this new entrepreneurial venture. He explains : Regenerative therapy is an international fast growing market. However it remains immature due to the limitations of stem cells manufacturing capabilities and the cost of treatments that still remains very high. Our ambition is to industrialise the manufacturing process to accelerate the use of stem cells in regenerative medicine and to become the market leader.

Despite the huge clinical potential of regenerative therapy, access to treatments and the cost remain major obstacles to its development. Today only the very rich can access cell therapy. Treatments can cost up to 350K per patient ! By streamlining the manufacturing process of stem cells, the major opportunity were offering is to industrialise the process associated with a very competitive cost price. Large scale stem cell manufacturing can cut costs by 10, maybe 100. Pierre Monsan adds.

A unique stem cell factory in EuropeTo be able to manufacture stem cell batches on a large scale, Cell-Easy has the latest research equipment and labs, built in accordance to the GMP (Good Manufacturing Practices) standards. They will open in the first quarter of 2020. By the end of 2020 the production capacity will reach 10 000 doses /year compared to its competitors producing a few hundred doses /year. Cell-Easy is planning to secure further capital investment to scale-up stem cell manufacturing and its international commercialisation.

Read more:
Cell-Easy Leads the Way Towards Tomorrow's Healthcare With Accessible Stem Cell Therapy - Business Wire

ANI | Updated: Nov 29, 2019 20:58 IST

Washington D.C. [USA], Nov 29 (ANI): Researchers have discovered a stem cell therapy that might help the heart recuperate from an attack.This study published in the journal Nature reported that injecting living or even dead heart stem cells into the injured hearts of mice triggers an acute inflammatory process, which in turn generates a wound healing-like response to enhance the mechanical properties of the injured area.Mediated by macrophage cells of the immune system, the secondary healing process provided a modest benefit to heart function after a heart attack, according to the principal investigator Jeffery Molkentin, PhD, director of Molecular Cardiovascular Microbiology a Cincinnati Children's Hospital Medical Center and a professor of the Howard Hughes Medical Institute (HHMI)."The innate immune response acutely altered cellular activity around the injured area of the heart so that it healed with a more optimized scar and improved contractile properties," Molkentin said.The findings build on a 2014 study published by the same research team. As in that earlier study, the current paper shows that injecting c-kit positive heart stem cells into damaged hearts as a strategy to regenerate cardiomyocytes doesn't work.The findings prompted Molkentin and his colleagues to conclude that there is a need to "re-evaluate the current planned cell therapy based clinical trials to ask how this therapy might really work."Researchers worked with two types of heart stem cells currently used in the clinical trials -- bone marrow mononuclear cells and cardiac progenitor cells.As they went through the process of testing and re-verifying their data under different conditions, they were surprised to discover that in addition to the two types of stem cells, injecting dead cells or even an inert chemical called zymosan also provided benefit to the heart by optimizing the healing process. Zymosan is a substance designed to induce an innate immune response.They reported that stem cells or zymosan therapies tested in this study altered immune cell responses that significantly decreased the formation of extracellular matrix connective tissue in the injury areas, while also improving the mechanical properties of the scar itself.Researchers also found that stem cells and other therapeutic substances like zymosan have to be injected directly into the hearts surrounding the area of infarction injury."Most of the current trials were also incorrectly designed because they infuse cells into the vasculature. Our results show that the injected material has to go directly into the heart tissue flanking the infarct region. This is where the healing is occurring and where the macrophages can work their magic," Molkentin explained. (ANI)

Continue reading here:
Researchers discover a stem cell therapy that can help heal injured heart - ANI News

A new business intelligence report released by Garner Insights with title Global Stem Cell Therapy Market Research Report 2019 that targets and provides comprehensive market analysis with prospects to 2024. The analysts of the study have garnered extensive research methodologies and data sources (i.e. Secondary & Primary Sources) in order to generate collective and useful information that delivers latest market undercurrents and industry trends.

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

Get a Sample PDF Report: https://www.garnerinsights.com/Global-Stem-Cell-Therapy-Market-2019-by-Company-Regions-Type-and-Application-Forecast-to-2024#request-sample

Some of key competitors or manufacturers included in the study are: Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix),

If you are involved in the Global Stem Cell Therapy industry or intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented by major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports, we can provide customization according to your requirement.

Market Segment by Type, covers: Autologous, Allogeneic

Market Segment by Applications, can be divided into: Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others,

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

What are the affecting elements that are made reference to in the report?

Market Scenario:The report further highlights the development trends in the global Stem Cell Therapy market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Key Market Highlights:The Stem Cell Therapy report gives a top to bottom examination on a portion of the key elements, involving income, cost, limit, limit usage rate, creation, generation rate, utilization, import/send out, supply/request, net, piece of the pie, CAGR, and gross edge. Furthermore, the report shows a far reaching investigation of the market development factors and their most recent patterns, alongside important market fragments and sub-portions.

Analytical Tools:The Global Stem Cell Therapy Market report incorporates the decisively examined and assessed information of the significant market members and their market scope utilizing various investigative devices. The diagnostic apparatuses incorporate Porters five powers examination, SWOT investigation, achievability study, and venture return investigation, which have been utilized to consider the development of the key players working in the market.

Get Discount on this Report: https://www.garnerinsights.com/Global-Stem-Cell-Therapy-Market-2019-by-Company-Regions-Type-and-Application-Forecast-to-2024#discount

Some of the Points cover in Global Stem Cell Therapy Market Research Report is:

Chapter 1: Overview of Global Stem Cell Therapy Market (2019-2024) Definition Specifications Classification Applications Regions

Chapter 2: Market Competition by Players/Suppliers 2019 and 2024 Manufacturing Cost Structure Raw Material and Suppliers Manufacturing Process Industry Chain Structure. Continued

The main points which are answered and covered in this Report are-

What will be the total Stem Cell Therapy Market in the coming years till 2024?What will be the key factors which will be overall affecting the industry?What are the various challenges addressed?Which are the major companies included?

Thank You For Visiting Our Report : you can likewise get singular part astute segment or locale insightful report form like Asia, United States, Europe.

View Full Report@ https://garnerinsights.com/Global-Stem-Cell-Therapy-Market-2019-by-Company-Regions-Type-and-Application-Forecast-to-2024#description

Here is the original post:
As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types...

Persistence Market Research(PMR), in its recent market report, suggests that the Stem Cell Therapy Market report is set to exceed US$ xx Mn/Bn. The report finds that the Stem Cell Therapy Market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period 2020.

The Stem Cell Therapy Market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Stem Cell Therapy Market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Stem Cell Therapy Market study provides reliable and authentic projections regarding the technical jargon.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/3253

The Stem Cell Therapy Market study answers critical questions including:

The content of the Stem Cell Therapy Market report includes the following insights:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/3253

All the players running in the global Stem Cell Therapy Market are elaborated thoroughly in the Stem Cell Therapy Market report on the basis of R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines, legal policies, and comparative analysis between the leading and emerging Stem Cell Therapy Market players.

Some of the major companies operating in the global stem cell therapy market are Mesoblast Ltd., Celgene Corporation, Aastrom Biosciences, Inc. and StemCells, Inc.

Key points covered in the report

Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/3253

Why choose PMR?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:Persistence Market Research305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

The rest is here:
Stem Cell Therapy Market Growth opportunities, Trends, Industry Analysis, and Forecast to 2020 - Kentucky Reports

Global Stem Cell Therapy Market Analysis

The recent report published by TMRR on the global Stem Cell Therapy market is an in-depth analysis of the overall prospects of the Stem Cell Therapy market in the upcoming years. The data collected from credible primary and secondary sources is accurately represented in the report backed up by relevant figures, graphs, and tables. The report includes a quantitative and qualitative analysis of the various aspects of the market by collecting data from the key participants in the Stem Cell Therapy market value chain.

The report reveals that the global Stem Cell Therapy market is set to grow at a CAGR of ~XX% over the forecast period (2019-2029) and surpass the value of ~US$XX by the end of 2029. The presented study also includes a thorough analysis of the micro and macroeconomic factors, regulatory framework, and current trends that are expected to influence the growth of the Stem Cell Therapy market during the assessment period.

Reports are available at cut-down rates for new customers! Offer expires soon!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

Vital Information Enclosed in the Stem Cell Therapy Market Report:

Important Queries Addressed in the Report

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

Stem Cell Therapy Market Segmentation

The market study put forward by TMRR segments the global Stem Cell Therapy market to offer a microscopic understanding of the various aspects of the Stem Cell Therapy market. The Stem Cell Therapy market is segmented on the basis of region, product type, end-user, and more.

The study offers a Y-o-Y growth projection of each market segment and sub-segment over the stipulated timeframe of the study.

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Why Buy from TMRR?

Read more:
Stem Cell Therapy Market Size, Share, Trends, and Opportunity Analysis by 2017 - 2025 - The Market Expedition

The Iranian regime faces the most serious popular challenge to its tyranny in 40 years. Sparked by a 50 percent hike in fuel prices last month, the uprising has spread to the whole country. Security forces have killed hundreds of protesters, and at one point they were even forced to shut down the internet a sign that the ayatollahs feared for the survival of their regime.

So its worth asking: Did our experts see this coming?

Nope: Most were too busy blasting President Trump. The prestige press and Twitterati spent the last few years railing against the president for trashing the nuclear deal and ratcheting up sanctions actions that had supposedly sent the Iranian people rallying around the flag.

Writing in February, New York Times Tehran correspondent Thomas Erdbrink described a nation standing behind its government. Braving a drenching rain, he wrote, Iranians came out in droves to march up Revolution Street to the capitals Freedom Monument for a huge state-backed rally commemorating the 40th anniversary of the Islamic Revolution.

Erdbrink also described Iranians parading effigies of Trump. But a reader would get little sense of a brutal regimes internal crisis of legitimacy that would explode a few months later.

You could hear a similar story on public radio, where PRIs popular show The Conversation warned this summer that Trumps sanctions would prove catastrophic. The presidents hard measures, the show suggested, would yield the classic rally-around-the-flag effect. Iranians are critical of their governments economic policies, but they also blame Trump for the hardships resulting from sanctions.

The same conventional wisdom traveled all the way down the journalistic totem pole, with Newsweeks David Brennan predicting last month that Trumps treatment of Iran will ensure America remains the Great Satan for years to come.

The very same ideas, often expressed in the very same words, emanated from Washingtons bien pensants at an alarming rate. Colum Lynch, Foreign Policys senior diplomatic correspondent, touted an academic poll in October that found conclusive evidence supposedly showing that Trumps sanctions had increased Iranian hostility toward the United States and boosted the popularity of Iranian hard-liners.

Writing in the same publication a year earlier, Philip Gordon of the Council on Foreign Relations and Robert Malley, a former Team Obama adviser, said the same thing only with more scorn. In Trumps vision, sanctions are a quasi-magical, multipurpose tool, they wrote, which might even lead the Iranian people, facing a collapsing economy, to rise up and sweep aside the Islamic regime. Thats an impressive wish-list. Its also utterly implausible.

Holly Dagres agreed in The Atlantic, judging Trumps policy to have produced meager results and noting that the heavy US pressure on Tehran in recent months has led to a rally-around-the-flag effect as Iranians push back against what many view as a Western imperialism.

Dror Michman, a Brookings Institution visiting fellow, concurred. Trumps sanctions, he wrote, will also have a huge impact on the Iranian president and will strengthen the radicals in Iran who always claimed that the West could not be trusted.

The unimprovably named Marik von Rennenkampf, an analyst appointed by Team Obama to the Pentagon, was even less subtle. Bellicose threats and confrontation lead to a rally-round-the-flag effect, he wrote in July in The Hill, where the Iranian population supports the government in power, regardless of how unpopular or authoritarian it may be.

As they say in Foggy Bottom: Oopsies.

The problem here isnt that so many experts were so wrong even the best thinkers can sometimes miss the mark. The problem is that all of our experts were wrong in exactly the same way, for precisely the same reason.

Blinded by their disdain for Trump, they could credit no narrative that didnt feature the president as the ultimate bumbler. Otherwise, theyd have had to accept two rather obvious points: that the billions paid by Team Obama kept the despised mullahs afloat; and that Trump imposing strict sanctions deprived the mullahs of the resources they need to keep oppressing the Iranian people.

So much was clear to anyone who actually bothered looking at Iran soberly. Sadly, this excludes more or less our entire liberal foreign policy establishment, most of academia and the media.

Its a troubling turn of events, but pay it little mind: As our experts are busy with their own #Resistance, a real resistance is unfolding in Iran.

Liel Liebovitz is a senior writer for Tablet. Twitter: @Liel

See the rest here:
Iran in flames and experts didnt foresee it due to Trump-hate blindness - New York Post

NewsEducationDialogue in the Dark has opened in London, giving visitors a sense of what it's like to not be able to see in a visual world

Wednesday, 4th December 2019, 6:01 am

Im in the pitch black and my heart is racing. Its not the kind of darkness that my eyes can adjust to I cant see a thing, not a single sliver of light.

My cane, which Ive been told to move slowly in front of me from left to right, clangs against what feels like a metal gate. Im seriously worried that Im going to smack into a wall, so I go slowly.

With my free hand, I reach out to check whats nearby, touching what might be a tree trunk. Dogs bark as I make my way through what Im pretty sure is a market stall, rummaging around to find something that feels like an onion. I dont know if its red or white, but I can feel the layers of peel.

i's education newsletter: latest schooling news

I try to work out what coins I have in my pocket in order to buy a coffee, but Im not sure Ive got the right money. The waitress tells me Ive given her 10p, not the pound coin I owe.

The blind leading people who want to learn

Im not actually outside on a street, but inside a studio space set up to feel like a real neighbourhood. This is Dialogue in the Dark, a new immersive experience in Hackney, east London, which shows people what its like to carry out ordinary daily activities when you cant see.

Of all the senses humans fear losing the most, sight is usually top of the list. Yet there are more than 350,000 people in the UK registered as blind or partially sighted, who every day find their way through a visual world.

Dialogue in the Dark was set up 27 years ago in Germany by Dr. Andreas Heinecke in 1988 who, after helping train a new, blind journalist at the radio station he worked at, realised how little he understood about blindness.

The social enterprise project now exists in over 40 countries across the world, opening for the first time this week in the UK. The idea is to help people understand what its like not to see, but it also provides employment opportunities for blind and partially sighted people.

Dialogue in the Dark

As I pick my way carefully over gravel and feel my way past a parked car, trying not to whack it with my cane, my guide Adara, a 34-year-old who has been blind all his life, helps me find my way with his voice. Its very disorientating at first- is Adara to my left or right, is he behind me? How far away? At one point I bump into him, feeling terrible about it- but of course, hes used to this in the real world.

I ask Adara how people with sight could change their behaviour to make his life easier. The bus drivers could make sure the volume is up on the next stop announcements, he says. He often has to ask them to turn it up. It would also be good if people looked where they were going, he sighs, albeit good naturedly. They just stop in the middle of the street.

When setting up the UK version of Dialogue in the Dark, the three founders sought advice and help from various organisations including The Royal Society for Blind Children about recruiting guides, and about how to make the experience as real as possible. Huseyin Gunduzler, who first had the idea to bring the concept to London after visiting it in Istanbul, says that the UK has some way to go with catering for the differently abled.

Leaving a genuine impression

I wanted this to get people thinking about how they might be able to help design the world better for those who cant see, to help inclusion and to have a more forward-thinking society. The aim is that at some point in the UK we have designed daily life to make it so accessible that we can stop using the word accessible because accessible will become the norm.

Dialogue in the Dark in Hackney has started fairly small- in Istanbul visitors experience going to an airport and getting on a plane - but Gunduzler hopes his exhibition will grow in time.

Dialogue in the Dark has left a genuine impression on me. Experiencing my sight taken away even for just one hour reminds me how much I take it for granted. Its made me better understand that its not that being blind is necessarily a tragedy in itself, but that the world is so badly set up for the differently abled.

Read the rest here:
I spent a day experiencing blindness, which made me realise how badly the world is set up - inews

Love Is Blind follows a young lady who cant see her mother or the suicidal man that her psychiatrist assigned to her due to her previous traumatic experiences. The film stars newcomer and lead Shannon Tarbet as Bess, Matthew Broderick as the father, Chlo Sevigny as the mother, Aidan Turner as Russell, and Benjamin Walker as Farmer.

In the interview with director Monty Whitebloom, he explained what precisely selective perception is, the deeper meaning of the story, and how traumatic experiences shape our vision. The questions and answers are below:

What made you want to make a movie about selective perception about a girl that cant see her mother or this suicidal man?Whitebloom: What I felt was the central idea of the whole film was really identity. Its an important subject matter. The whole idea of who somebody is and what you think you are or what you think you see around youis that really real, is that fake, or is there truth to that. The story of Bess with this metaphor of selective blindness is really an interesting concept about not being able to see or not wanting to see whats right in front of youwhether that be good, bad, or indifferent. That is a really interesting jumping-off point to explore the ideas of love, the ideas of companionship, connection, how you meet people and have a better life.

what you think you are or what you think you see around youis that really real, is that fake, or is there truth to that.

What have you learned about selective perception in making this film? Did you have to do some research? Is this real? How does this happen?The selective perception within the film isnt actually a real condition, but there are various forms of blindness where you get face blindness. The most obvious cases, cant recognize their name or dont know who they are. This is called face blindness, so face recognition is a real condition, even though weve met people, we cant remember who they are. I did quite a lot of research into that. The whole idea of sight of how and what one sees is really interesting thing. Obviously, sight and the idea of seeing is believing, in what you see and how important it was. I was always fascinated by that subject matter. I could relate to that experience, not quite selective; but its certainly the idea of how important sight is and when you cant see something. Obviously, Bess is dealing with a mental condition more than a physical one.

Go here to see the original:
Selective Perception Demonstrated in Love Is Blind With Director Monty Whitebloom - Film Threat